<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01472055</url>
  </required_header>
  <id_info>
    <org_study_id>SNUCH-SCT-1101</org_study_id>
    <nct_id>NCT01472055</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation</brief_title>
  <official_title>Pharmacokinetic Study of Fludarabine in Pediatric Hematopoietic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Food and Drug Safety, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to analysis of the pharmacokinetics of fludarabine for
      hematopoietic stem cell transplantation in pediatric patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Fludarabine is a commonly used chemotherapeutic agent for hematopoietic stem cell
      transplantation in children. However, no pharmacokinetic study has thus far been conducted in
      pediatric patients. Fludarabine can cause adverse reactions which include neurotoxicity,
      damage to lungs. Pharmacokinetic study is critical to predict the safety of fludarabine in
      pediatric patients.

      Through an individualized pharmacokinetic study (which entails numerous samplings) of
      fludarabine in pediatric patients, this study aims to develop a sampling-minimized analysis
      method and study the population pharmacokinetics.

      Through a pharmacokinetic analysis, we aim to evaluate whether pediatric patients show
      similar population pharmacokinetics of adults, for whom fludarabine is authorized, and
      evaluate the safety (toxicity) and efficacy (event free survival).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2011</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients</measure>
    <time_frame>0hr (pre-dose), 30 min, 1, 3, 5, 8, 24hrs post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparative analysis of the pharmacokinetics of fludarabine in pediatric and adult patients</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of toxicity, event free survival according to the pharmacokinetics of fludarabine</measure>
    <time_frame>1, 3, 6 and 12 months after transplantation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of therapy related toxicity, significant adverse reaction</measure>
    <time_frame>for 4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Chronic Leukemia</condition>
  <condition>Severe Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>Fludarabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Analysis of the pharmacokinetics of fludarabine for hematopoietic stem cell transplantation in pediatric patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 40 mg/m^2 once a day intravenous administration over 30 min
Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr
Population pharmacokinetics analysis
Comparative analysis of population pharmacokinetics in pediatric and adult patients
Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate</description>
    <arm_group_label>Fludarabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Conditioning regimen including fludarabine

          2. Age: &lt; 19 years old

          3. Functional class: ECOG 0-2

          4. No loss of function of major organs. Criteria may be individualized.

               -  Heart: shortening fraction &gt; 30%, ejection fraction &gt; 45%.

               -  Liver: total bilirubin &lt; 2 ⅹ upper limit of normal; ALT &lt; 3 ⅹ upper limit of
                  normal.

               -  Kidney: creatinine &lt; 2 ⅹ normal or a creatinine clearance (GFR) &gt; 60
                  ml/min/1.73m2.

          5. No active viral or fungal infection

          6. Appropriate hematopoietic stem cell donor

          7. Informed consent from patients' parents

        Exclusion Criteria:

          1. Pregnant or breast feeding

          2. Disease progression due to clinical test

          3. Psychiatric disease may interfere with clinical test

          4. Whether attending physician consider the patient inappropriate for study enrollment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung Jin Kang, MD., PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hyoung Jin Kang, MD, PhD</last_name>
    <phone>+82 2 2072 0177</phone>
    <email>kanghj@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji Won Lee, MD</last_name>
    <phone>+82 2 2072 3452</phone>
    <email>agnesjw@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Daehangno, Jongno-gu</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyoung Jin Kang, MD, PhD</last_name>
      <phone>+82 2 2072 0177</phone>
      <email>kanghj@snu.ac.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ji Won Lee, MD</last_name>
      <phone>+82 2 2072 3452</phone>
      <email>agnesjw@hanmail.net</email>
    </contact_backup>
    <investigator>
      <last_name>Hyoung Jin Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 6, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>August 18, 2014</last_update_submitted>
  <last_update_submitted_qc>August 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2014</last_update_posted>
  <keyword>Hematopoietic stem cell transplantation with fludarabine based conditioning</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

